Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Significance and Function of MicroRNA-7 in Oesophageal Squamous Cell Carcinoma

KEIGO HARA, TATSUYA MIYAZAKI, TAKEHIKO YOKOBORI, TOMONORI YOSHIDA, YUJI KUMAKURA, HIROAKI HONJYO, MAKOTO SAKAI, MAKOTO SOHDA, MINORU FUKUCHI and HIROYUKI KUWANO
Anticancer Research March 2017, 37 (3) 1043-1048;
KEIGO HARA
Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TATSUYA MIYAZAKI
Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tatsuyamiyazaki@gunma-u.ac.jp
TAKEHIKO YOKOBORI
Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOMONORI YOSHIDA
Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUJI KUMAKURA
Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROAKI HONJYO
Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MAKOTO SAKAI
Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MAKOTO SOHDA
Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MINORU FUKUCHI
Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROYUKI KUWANO
Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: We detected microRNA-7 (miR-7) as being specific for oesophageal squamous cell carcinoma (ESCC) by using database analysis. However, the significance of miR-7 in clinical ESCC remains unexplored. This study aimed to clarify the clinicopathological significance of miR-7 in ESCC, and investigate miR-7 function. Materials and Methods: Quantitative TaqMan reverse transcription polymerase chain reaction was used to evaluate miR-7 expression in 85 ESCC samples to determine the clinicopathological significance of miR-7 expression. The regulation of proliferation by miR-7 was examined with miR-7 precursor-transfected cells. Results: The expression of miR-7 in ESCC was higher than that in normal tissues. Low expression levels of miR-7 were associated with poor prognosis. Multivariate analysis indicated that low miR-7 expression was an independent prognostic factor for poor survival. In vitro assays showed miR-7 precursor treatment suppressed the proliferation of ESCC cells. Conclusion: miR-7 might be a promising prognostic marker and therapeutic target in ESCC.

  • microRNA
  • oesophageal cancer
  • prognostic marker

Survival of patients with advanced oesophageal squamous cell carcinoma (ESCC) remains poor regardless of improvements in perioperative management and definitive and adjuvant therapy (1-3). Locally advanced ESCC directly invades adjacent organs; this increases local recurrence and makes radical surgical resection difficult. Moreover, such ESCC cases exhibit early lymphatic and frequent haematogenous dissemination compared with other types of gastrointestinal cancer (4, 5). Therefore, markers that can predict ESCC progression and prognosis correctly and reliably are needed for improving survival of patients with ESCC.

MicroRNAs (miRs) have attracted attention as important regulators of gene expression. These small non-coding RNAs are 18-25 nucleotides in length and partially bind to the 3’-untranslated region of target mRNAs. This binding of miR and mRNA leads to mRNA degradation or translational repression (6). Depending on their targets, many miRs play important roles in proliferation, apoptosis, differentiation, and cancer progression. In order to find cancer-specific miRs in ESCC, we re-analyzed data with the series accession number GSE6188 in the Gene Expression Omnibus public microarray database (7). As a result, we detected miR-196a, miR-7, and miR-503 as being up-regulated by 6.64-, 4.31- and 3.65-fold, respectively, in ESCC compared to normal oesophageal mucosa. The function and expression significance of miR-196a and miR-503 in ESCC have been reported (8-10). In addition, Fu et al. reported that the expression level of miR-7 in primary ESCC tissue was higher than that in non-cancerous tissues (11), and Dong et al. described serum miR-7 expression in patients with ESCC as being higher than that in healthy volunteers (12). However, few studies are available on the significance and function of miR-7 expression in ESCC.

The purpose of this study was to clarify the clinicopathological significance of miR-7 expression in ESCC, and to investigate the function of miR-7 in ESCC cells in vitro. Therefore, we examined the expression of miR-7 in clinical ESCC samples and the miR-7-mediated regulation of proliferation in ESCC cells in vitro.

Materials and Methods

Cancer-specific miR detection by re-analysis of GSE6188. Re-analysis for GSE6188 was performed by Subio Platform (Subio Inc. Tokyo, Japan). Probes significantly different between cancerous tissues (153 samples) and normal tissues (104 samples) were extracted with a fold-change greater than 3.5 and a t-test (equal variance) with p<0.05. The probes corresponding to over half of 48 donors with two cancerous tissues and two adjacent normal tissues and whose clinical characteristics were significantly different were selected as the three up-regulated miRs.

Clinical samples and RNA isolation. Samples of primary ESCC (n=85) and corresponding normal oesophageal epithelium (n=85) were obtained from patients with ESCC who had undergone potentially curative surgery at the Department of General Surgical Science, Gunma University, Japan, between 1999 and 2006. These samples were used after obtaining written informed consent in accordance with institutional guidelines and the Declaration of Helsinki (approval number 1457). The pathological features of the samples were classified according to the sixth edition of the TNM Classification of the International Union against Cancer (13). The surgical procedures were classified as curative; there was no evidence of residual tumour tissue, and the resected margins were microscopically free of tumour (R0). Normal tissue samples were obtained away from the centre of the tumour in surgical specimens. All samples were immediately frozen in liquid nitrogen and stored at −80°C until RNA extraction. Total RNA was extracted using the miRNeasy Mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions.

Evaluation of miR-7 expression in clinical ESCC samples. For quantitative real-time reverse transcriptase–polymerase chain reaction (RT-PCR) of miR-7, cDNA was synthesized from 10 ng total RNA using the TaqMan MicroRNA Reverse Transcription kit and specific stem-loop reverse transcription primers (Applied Biosystems, Foster city, CA, USA) according to the manufacturer's protocol. PCR was performed in a LightCycler™ 480 system (Roche Diagnostics GmbH, Mannheim, Germany). The 20 μl PCR mixture included in the LightCycler 480 Probes Master kit (Roche Diagnostics GmbH, Mannheim, Germany) was incubated in a 96-well optical plate at 95°C for 10 min, and then subjected to 45 cycles of 95°C for 10 seconds and 60°C for 30 sec. Expression levels of miR-7 were normalized to that of the small nuclear RNA RNU6B and analysed using the 2−ΔΔCt method.

Cell line. The human ESCC cell line TE-8 was obtained from the RIKEN BioResource Center (RIKEN BRC, Tukuba, Ibaraki, Japan). TE-8 cells were cultured in RPMI_1640 medium (Wako, Osaka, Japan) supplemented with 10% foetal bovine serum and 1% penicillin–streptomycin antibiotics (Invitrogen, Carlsbad, CA, USA).

Transfection of the miR-7 precursor. Pre-miR™ miRNA Precursor Molecule mimicking miR-7 (premiR-7; Applied Biosystems) or non-specific control miR (Pre-miR™ miRNA Negative Control #1; premiR-nc; Applied Biosystems) was transfected at 30 pmol/l into TE-8 cells by using an electroporator (CUY 21 EDIT II; BEX, Tokyo, Japan) according to protocol. Before conducting assays, we confirmed that miR-7 expression in premiR-7 precursor-treated cells was significantly higher than that in the parent TE-8 cells and control miR-treated cells using RT-PCR.

Proliferation assay. Cell proliferation analysis was performed using cells that had been transfected with negative control or premiR-7. The cells were plated in 96-well plates in 100 μl of medium at approximately 3,000 cells per well. For the quantification of cell viability in the WST-8 assay (Dojindo Lab., Tokyo, Japan), 10 μl of the cell counting solution was added to each well after 0, 24, 48, and 72 h and plates were incubated at 37°C for another 2 hours. The cell proliferation rate was then determined by measuring the absorbance of the well at 450 nm with the reference wavelength set at 650 nm. Absorbance was read using a microtitre plate reader (Molecular Devices, Sunnyvale, CA, USA).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Clinical significance of miR-7 expression in oesophageal squamous cell carcinoma (ESCC) samples from the re-analysed GSE6188 data. miR-7 levels were shown to be higher in ESCC than those of the adjacent normal tissues.

Statistical analysis. Differences between groups were estimated using Student's t-test, the chi-square test, and the repeated measures ANOVA. Kaplan–Meier curves were generated for overall survival, and statistical significance was determined using the log-rank test. A probability value of less than 0.05 was considered significant. All statistical analyses were performed using JMP software (SAS Institute, Cary, NC, USA).

Results

Clinical significance of miR-7 expression in patients with ESCC. Re-analysis of GSE6188 revealed miR-196a, miR-7 and miR-503 to be up-regulated in ESCC Among them, we focused on miR-7 (Figure 1) in order to clarify the clinical significance of miR-7 expression in clinical ESCC samples. We assessed miR-7 expression in 85 ESCC samples and 85 paired non-cancerous samples. The expression of miR-7 was significantly greater in tumour than in normal tissue (p<0.001) (Figure 2A).

We divided the 85 patients with ESCC into two groups according to the tumour/normal tissue ratio (T/N) for miR-7 expression, and the cut-off point was defined as T/N=8.5 (high-expression group, T/N≥8.5, n=31; low-expression group, T/N<8.5, n=54). Clinicopathological factors did not differ between the miR-7 low-expression and high-expression groups (Table I).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

miR-7 expression in 85 oesophageal squamous cell carcinoma (ESCC) samples of our cohort and its relationship with survival. A: The expression levels of miR-7 in tumour (T) and normal (N) tissue. Overall (B) and disease-free (C) survival curves of patients with ESCC according to miR-7 expression using a cut-off of 8.5.

Prognostic significance of miR-7 expression in patients with ESCC. The overall survival curve revealed that patients in the low-miR-7 expression group had a significantly poorer prognosis than those in the high-expression group (p=0.048) (Figure 2B). In univariate and multivariate analyses, low expression of miR-7 in ESCC was found to be a significant independent prognostic factor (Table II). In multivariate analysis, other investigated clinicopathological factors were not revealed as significant independent predictors of poor prognosis in this ESCC cohort, whereas low expression of miR-7 in primary ESCC remained prognostically significant with regard to overall survival.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Relationship between miR-7 expression and clinicopathological features.

Regulation of proliferation by miR-7 in ESCC cells. We confirmed that the expression of miR-7 in miR-7 precursor-transfected cells was higher than that in control cells (Figure 3A). Proliferation of miR-7 precursor-transfected cells was significantly reduced from 48 h compared with control cells (p<0.05) (Figure 3B).

Discussion

In this study, we clarified that a low expression level of miR-7 in ESCC was an independent prognostic factor in spite of cancer-specific high expression and weak association with increasing severity of clinicopathological factors. On in vitro analysis, we found that the proliferation of miR-7 precursor-treated ESCC cells decreased compared with the control cells.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Proliferation potency of miR-7 precursor-transfected cells. A: Expression of miR-7 was shown to be significantly increased in miR-7 precursor-treated cells. B: The proliferation rate was reduced in miR-7 precursor-treated cells in comparison with that of control miR-treated cells. The data represent mean±SD. *Significantly different at p<0.05.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Results of univariate and multivariate analyses of clinicopathological Factors affecting the overall survival rate following surgery.

We focused on miR-7 as an ESCC-specific miR, and initially predicted that miR-7 might function as a tumour promoter in ESCC. The expression of miR-7 was found to be increased in ESCC compared with normal tissue; however, patients with ESCC with low miR-7 had a poorer prognosis than those with high expression of miR-7. Similar to our findings in ESCC, previous study revealed that miR-7 expression in colorectal cancer cells was higher than that in normal cells but that the prognosis was worse in the patients with low expression than in those with high expression (14). On the other hand, down-regulation of miR-7 expression has been described in thyroid cancer and mesothelioma (15, 16). The detailed mechanism of miR-7 regulation in ESCC is unclear; however, other researchers have reported that E2F transcription factors regulate miR-7 expression (17) and that USP18 negatively regulate miR-7 expression (18). Moreover, Chuo et al. reported that the activation of epidermal growth factor receptor (EGFR) in lung cancer cells stimulated miR-7 expression via extracellular signal-regulated kinase (19). E2F and EGFR have been reported to be expressed in ESCC (20, 21); this suggests that miR-7 might be at least partially regulated by the activation of cancer-specific signals such as E2F and EGFR.

Down-regulation of miR-7 in ESCC samples was not associated with progression of existing clinicopathological factors; however, patients with miR-7 down-regulation had poorer prognosis than those with high miR-7 expression. miR-7 was reported to be suppressed in chemotherapy-resistant cancer cells (22-24). Moreover, Lee et al. described that miR-7 induction suppressed EGFR and protein kinase B expression, and induced increased sensitivity to radiation treatment in several cancer cell lines (25). Multiple targets have been identified for miR-7, including EGFR, human epidermal growth factor receptor 2, Raf-1 proto-oncogene, multidrug resistance-associated protein 1, focal adhesion kinase, insulin-like growth factor 1 receptor, B-cell lymphoma 2, and SATB homeobox1, which are associated with therapeutic resistance and malignant potential in several cancer types (14, 23, 26-30). In this study, we found that miR-7 precursor treatment suppressed cell growth by ESCC cells. From these observations, we suggest that miR-7 induction in patients with ESCC might be useful as a therapeutic strategy to overcome resistance to chemotherapy or radiation therapy, which are very important therapeutic tools for patients with ESCC.

In this study, we showed that miR-7 treatment induced an anticancer effect on ESCC cells in vitro. This finding indicates that administration of miR-7 to patients with ESCC might be a useful means of attacking the ESCC cells. In fact, previous reports have demonstrated that small RNAs administered systemically to humans were able to inhibit specific genes via an RNA interference mechanism, and these therapeutic strategies have attracted attention (31-35). Currently, the role of miR-7 in the human circulatory system is not well understood; however, it has been reported that high levels of serum miR-7 were associated with high sensitivity to chemoradiation in patients with ESCC (12). Administration of miR-7 to the circulation might function as a sensitizer to chemotherapy or radiation therapy. In future, determination of an effective means to deliver miRs to cancerous tissue is an important task.

In conclusion, our data indicate that down-regulation of miR-7 is associated with poor prognosis and reduced proliferative ability in ESCC. The level of miR-7 in ESCC might be a powerful prognostic factor independent of existing clinicopathological factors. The regulation of miR-7 could provide a promising novel possibility for targeted therapeutic strategies in ESCC.

Acknowledgements

This work was supported in part by the following grants and foundations: Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS), grant numbers 26461969, 15K10129, and 15K10085; and Gunma University Initiative for Advanced Research (GIAR).

Footnotes

  • Conflicts of Interest

    None of the Authors has any conflict of interest to declare in regard to this study.

  • Received January 5, 2017.
  • Revision received February 19, 2017.
  • Accepted February 21, 2017.
  • Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

References

  1. ↵
    1. Malthaner RA,
    2. Wong RK,
    3. Rumble RB,
    4. Zuraw L
    : Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med 2: 35, 2004.
    OpenUrlCrossRefPubMed
    1. Gebski V,
    2. Burmeister B,
    3. Smithers BM,
    4. Foo K,
    5. Zalcberg J,
    6. Simes J
    : Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8: 226-234, 2007.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Tepper J,
    2. Krasna MJ,
    3. Niedzwiecki D,
    4. Hollis D,
    5. Reed CE,
    6. Goldberg R,
    7. Kiel K,
    8. Willett C,
    9. Sugarbaker D,
    10. Mayer R
    : Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 26: 1086-1092, 2008.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Enzinger PC,
    2. Mayer RJ
    : Esophageal cancer. N Engl J Med 349: 2241-2252, 2003.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Parkin DM,
    2. Bray F,
    3. Ferlay J,
    4. Pisani P
    : Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Valencia-Sanchez MA,
    2. Liu J,
    3. Hannon GJ,
    4. Parker R
    : Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 20: 515-524, 2006.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Guo Y,
    2. Chen Z,
    3. Zhang L,
    4. Zhou F,
    5. Shi S,
    6. Feng X,
    7. Li B,
    8. Meng X,
    9. Ma X,
    10. Luo M,
    11. Shao K,
    12. Li N,
    13. Qiu B,
    14. Mitchelson K,
    15. Cheng J,
    16. He J
    : Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res 68: 26-33, 2008.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Ma Y,
    2. Wang B,
    3. Guo Y,
    4. Zhang Y,
    5. Huang S,
    6. Bao X,
    7. Bai M
    : Inhibition of miR-196a affects esophageal cancer cell growth in vitro. Biomed Pharmacother 84: 22-27, 2016.
    OpenUrl
    1. Ide S,
    2. Toiyama Y,
    3. Shimura T,
    4. Kawamura M,
    5. Yasuda H,
    6. Saigusa S,
    7. Ohi M,
    8. Tanaka K,
    9. Mohri Y,
    10. Kusunoki M
    : MicroRNA-503 promotes tumor progression and acts as a novel biomarker for prognosis in oesophageal cancer. Anticancer Res 35: 1447-1451, 2015.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Zhao K,
    2. Chen BJ,
    3. Chen ZG,
    4. Zhang YJ,
    5. Xu D,
    6. Liu Q
    : Effect of miR-503 down-regulation on growth and invasion of esophagus carcinoma and related immune function. Med Sci Monit 21: 3564-3569, 2015.
    OpenUrl
  9. ↵
    1. Fu HL,
    2. Wu DP,
    3. Wang XF,
    4. Wang JG,
    5. Jiao F,
    6. Song LL,
    7. Xie H,
    8. Wen XY,
    9. Shan HS,
    10. Du YX,
    11. Zhao YP
    : Altered miRNA expression is associated with differentiation, invasion, and metastasis of esophageal squamous cell carcinoma (ESCC) in patients from Huaian, China. Cell Biochem Biophys 67: 657-668, 2013.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Dong W,
    2. Li B,
    3. Wang J,
    4. Song Y,
    5. Zhang Z,
    6. Fu C,
    7. Zhang P
    : Diagnostic and predictive significance of serum microRNA-7 in esophageal squamous cell carcinoma. Oncol Rep 35: 1449-1456, 2016.
    OpenUrl
  11. ↵
    1. Sobin LH,
    2. Wittekind CH
    : TNM Classification of Malignant Tumours, 6th edition. John Wiley & Sons, Hoboken, New Jersey, USA, 2002.
  12. ↵
    1. Suto T,
    2. Yokobori T,
    3. Yajima R,
    4. Morita H,
    5. Fujii T,
    6. Yamaguchi S,
    7. Altan B,
    8. Tsutsumi S,
    9. Asao T,
    10. Kuwano H
    : microRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation. Carcinogenesis 36: 338-345, 2014.
    OpenUrl
  13. ↵
    1. Yue K,
    2. Wang X,
    3. Wu Y,
    4. Zhou X,
    5. He Q,
    6. Duan Y
    : microRNA-7 regulates cell growth, migration and invasion via direct targeting of PAK1 in thyroid cancer. Mol Med Rep 14: 2127-2134, 2016.
    OpenUrl
  14. ↵
    1. Guled M,
    2. Lahti L,
    3. Lindholm PM,
    4. Salmenkivi K,
    5. Bagwan I,
    6. Nicholson AG,
    7. Knuutila S
    : CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma -A miRNA microarray analysis. Genes Chromosomes Cancer 48: 615-623, 2009.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Tazawa H,
    2. Yano S,
    3. Yoshida R,
    4. Yamasaki Y,
    5. Sasaki T,
    6. Hashimoto Y,
    7. Kuroda S,
    8. Ouchi M,
    9. Onishi T,
    10. Uno F,
    11. Kagawa S,
    12. Urata Y,
    13. Fujiwara T
    : Genetically engineered oncolytic adenovirus induces autophagic cell death through an E2F1-microRNA-7-epidermal growth factor receptor axis. Int J Cancer 131: 2939-2950, 2012.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Duex JE,
    2. Comeau L,
    3. Sorkin A,
    4. Purow B,
    5. Kefas B
    : USP18 regulates epidermal growth factor (EGF) receptor expression and cancer cell survival via microRNA-7. J Biol Chem 286: 25377-25386, 2011.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Chou YT,
    2. Lin HH,
    3. Lien YC,
    4. Wang YH,
    5. Hong CF,
    6. Kao YR,
    7. Lin SC,
    8. Chang YC,
    9. Lin SY,
    10. Chen SJ,
    11. Chen HC,
    12. Yeh SD,
    13. Wu CW
    : EGFR promotes lung tumorigenesis by activating miR-7 through a RAS/ERK/MYC pathway that targets the ETS2 transcriptional repressor ERF. Cancer Res 70: 8822-8831, 2010.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Yamazaki K,
    2. Hasegawa M,
    3. Ohoka I,
    4. Hanami K,
    5. Asoh A,
    6. Nagano T,
    7. Sugano I,
    8. Ishida Y
    : Increased E2F-1 expression via tumour cell proliferation and decreased apoptosis are correlated with adverse prognosis in patients with squamous cell carcinoma of the oesophagus. J Clin Pathol 58: 904-910, 2005.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Mandard AM,
    2. Hainaut P,
    3. Hollstein M
    : Genetic steps in the development of squamous cell carcinoma of the esophagus. Mutat Res 462: 335-342, 2000.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Kastl L,
    2. Brown I,
    3. Schofield AC
    : miRNA-34a is associated with docetaxel resistance in human breast cancer cells. Breast Cancer Res Treat 131: 445-454, 2012.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Pogribny IP,
    2. Filkowski JN,
    3. Tryndyak VP,
    4. Golubov A,
    5. Shpyleva SI,
    6. Kovalchuk O
    : Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer 127: 1785-1794, 2010.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Wu XM,
    2. Shao XQ,
    3. Meng XX,
    4. Zhang XN,
    5. Zhu L,
    6. Liu SX,
    7. Lin J,
    8. Xiao HS
    : Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells. Acta Pharmacol Sin 32: 259-269, 2011.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Lee KM,
    2. Choi EJ,
    3. Kim IA
    : microRNA-7 increases radiosensitivity of human cancer cells with activated EGFR-associated signaling. Radiother Oncol 101: 171-176, 2011.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Giles KM,
    2. Barker A,
    3. Zhang PM,
    4. Epis MR,
    5. Leedman PJ
    : MicroRNA regulation of growth factor receptor signaling in human cancer cells. Methods Mol Biol 676: 147-163, 2011.
    OpenUrlCrossRefPubMed
    1. Kong X,
    2. Li G,
    3. Yuan Y,
    4. He Y,
    5. Wu X,
    6. Zhang W,
    7. Wu Z,
    8. Chen T,
    9. Wu W,
    10. Lobie PE,
    11. Zhu T
    : MicroRNA-7 inhibits epithelial-to-mesenchymal transition and metastasis of breast cancer cells via targeting FAK expression. PloS One 7: e41523, 2012.
    OpenUrlCrossRefPubMed
    1. Jiang L,
    2. Liu X,
    3. Chen Z,
    4. Jin Y,
    5. Heidbreder CE,
    6. Kolokythas A,
    7. Wang A,
    8. Dai Y,
    9. Zhou X
    : MicroRNA-7 targets IGF1R (insulin-like growth factor 1 receptor) in tongue squamous cell carcinoma cells. Biochem J 432: 199-205, 2010.
    OpenUrlAbstract/FREE Full Text
    1. Xiong S,
    2. Zheng Y,
    3. Jiang P,
    4. Liu X,
    5. Chu Y
    : MicroRNA-7 inhibits the growth of human non-small cell lung cancer A549 cells through targeting BCL-2. Int J Biol Sci 7: 805-814, 2011.
    OpenUrlCrossRefPubMed
  25. ↵
    1. McInnes N,
    2. Sadlon TJ,
    3. Brown CY,
    4. Pederson S,
    5. Beyer M,
    6. Shultze JL,
    7. McColl S,
    8. Goodall GJ,
    9. Barry SC
    : FOXP3 and FOXP3-regulated microRNAs suppress SATB1 in breast cancer cells. Oncogene 31: 1045-1054, 2012.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Davis ME,
    2. Zuckerman JE,
    3. Choi CH,
    4. Seligson D,
    5. Tolcher A,
    6. Alabi CA,
    7. Yen Y,
    8. Heifel JD,
    9. Ribas A
    : Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464: 1067-1070, 2010.
    OpenUrlCrossRefPubMed
    1. Soifer HS,
    2. Rossi JJ,
    3. Saetrom P
    : MicroRNAs in disease and potential therapeutic applications. Mol Ther 15: 2070-2079, 2007.
    OpenUrlCrossRefPubMed
    1. Pecot CV,
    2. Calin GA,
    3. Coleman RL,
    4. Lopez-Berestein G,
    5. Sood AK
    : RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 11: 59-67, 2011.
    OpenUrlCrossRefPubMed
    1. Elmen J,
    2. Lindow M,
    3. Schutz S,
    4. Lawrence M,
    5. Petri A,
    6. Obad S,
    7. Lindholm M,
    8. Hedtjarn M,
    9. Hansen HF,
    10. Berger U,
    11. Gullans S,
    12. Kearney P,
    13. Sarnow P,
    14. Straarup EM,
    15. Kauppinen S
    : LNA-mediated microRNA silencing in non-human primates. Nature 452: 896-899, 2008.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Silvestri P,
    2. Di Russo C,
    3. Rigattieri S,
    4. Fedele S,
    5. Todaro D,
    6. Ferraiuolo G,
    7. Altamura G,
    8. Loshivao P
    : MicroRNAs and ischemic heart disease: towards a better comprehension of pathogenesis, new diagnostic tools and new therapeutic targets. Recent Pat Cardiovasc Drug Discov 4: 109-118, 2009.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 37 (3)
Anticancer Research
Vol. 37, Issue 3
March 2017
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Significance and Function of MicroRNA-7 in Oesophageal Squamous Cell Carcinoma
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
5 + 5 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Significance and Function of MicroRNA-7 in Oesophageal Squamous Cell Carcinoma
KEIGO HARA, TATSUYA MIYAZAKI, TAKEHIKO YOKOBORI, TOMONORI YOSHIDA, YUJI KUMAKURA, HIROAKI HONJYO, MAKOTO SAKAI, MAKOTO SOHDA, MINORU FUKUCHI, HIROYUKI KUWANO
Anticancer Research Mar 2017, 37 (3) 1043-1048;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Significance and Function of MicroRNA-7 in Oesophageal Squamous Cell Carcinoma
KEIGO HARA, TATSUYA MIYAZAKI, TAKEHIKO YOKOBORI, TOMONORI YOSHIDA, YUJI KUMAKURA, HIROAKI HONJYO, MAKOTO SAKAI, MAKOTO SOHDA, MINORU FUKUCHI, HIROYUKI KUWANO
Anticancer Research Mar 2017, 37 (3) 1043-1048;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • PTPN3 Could Βe a Therapeutic Target of Pancreatic Cancer
  • Murine Double Minute 2 Antagonist Nutlin-3 Enhanced Chemosensitivity in Esophageal Squamous Cell Carcinoma
  • Potent Imidazothiazole-based Inhibitor of BRAF V600E Overcomes Acquired Resistance via Inhibition of RAF Dimerization in PLX4032-resistant Melanoma
Show more Experimental Studies

Similar Articles

Keywords

  • microRNA
  • oesophageal cancer
  • prognostic marker
Anticancer Research

© 2022 Anticancer Research

Powered by HighWire